Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Clinical Research Development Unit, Afzalipour Hospital' Kerman University of Medical Sciences, Kerman, Iran.
BMC Infect Dis. 2024 Jun 3;24(1):553. doi: 10.1186/s12879-024-09373-2.
The emergence of coronavirus disease 2019 (COVID-19) as a global health emergency necessitates continued investigation of the disease progression. This study investigated the relationship between eosinophilia and the severity of COVID-19 in chronic obstructive pulmonary disease (COPD) patients.
This cross-sectional study was conducted on 73 COPD patients infected by COVID-19 in Afzalipour Hospital, Iran. Peripheral blood samples were collected for hematological parameter testing, including eosinophil percentage, using Giemsa staining. Eosinophilia was defined as≥ 2% and non-eosinophilia as< 2%. The severity of pulmonary involvement was determined based on chest CT severity score (CT-SS) (based on the degree of involvement of the lung lobes, 0%: 0 points, 1-25%: 1 point, 26-50%: 2 points, 51-75%: 3 points, and 76-100%: 4 points). The CT-SS was the sum of the scores of the five lobes (range 0-20).
The average age of patients was 67.90±13.71 years, and most were male (54.8%). Non-eosinophilic COPD patients were associated with more severe COVID-19 (P= 0.01) and lower oxygen saturation (P= 0.001). In addition, the study revealed a significant difference in the chest CT severity score (CT-SS) between non-eosinophilic (9.76±0.7) and eosinophilic COPD patients (6.26±0.63) (P< 0.001). Although non-eosinophilic COPD patients had a higher mortality rate, this difference was not statistically significant (P= 0.16).
Our study demonstrated that reduced peripheral blood eosinophil levels in COPD patients with COVID-19 correlate with unfavorable outcomes. Understanding this association can help us identify high-risk COPD patients and take appropriate management strategies to improve their prognosis.
2019 年冠状病毒病（COVID-19）作为全球卫生紧急情况的出现需要继续研究疾病的进展。本研究调查了嗜酸性粒细胞增多与慢性阻塞性肺疾病（COPD）患者 COVID-19 严重程度之间的关系。
本横断面研究在伊朗阿夫扎利普尔医院对 73 例感染 COVID-19 的 COPD 患者进行。采集外周血样进行血液学参数检测，包括使用吉姆萨染色的嗜酸性粒细胞百分比。嗜酸性粒细胞增多定义为≥2%，非嗜酸性粒细胞增多定义为<2%。根据胸部 CT 严重程度评分（CT-SS）（根据肺叶受累程度，0%：0 分，1-25%：1 分，26-50%：2 分，51-75%：3 分，76-100%：4 分）确定肺部受累的严重程度。CT-SS 是五个肺叶评分的总和（范围 0-20）。
患者的平均年龄为 67.90±13.71 岁，大多数为男性（54.8%）。非嗜酸性粒细胞性 COPD 患者与更严重的 COVID-19（P=0.01）和更低的氧饱和度（P=0.001）相关。此外，研究还发现非嗜酸性粒细胞性（9.76±0.7）和嗜酸性粒细胞性 COPD 患者之间的胸部 CT 严重程度评分（CT-SS）存在显著差异（6.26±0.63）（P<0.001）。虽然非嗜酸性粒细胞性 COPD 患者的死亡率较高，但差异无统计学意义（P=0.16）。
我们的研究表明，COVID-19 合并 COPD 患者外周血嗜酸性粒细胞水平降低与不良结局相关。了解这种关联可以帮助我们识别高危 COPD 患者，并采取适当的管理策略来改善他们的预后。
